EA201590460A1 - METHOD AND MEANS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY (+) RNA-CONTAINING VIRUSES - Google Patents

METHOD AND MEANS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY (+) RNA-CONTAINING VIRUSES

Info

Publication number
EA201590460A1
EA201590460A1 EA201590460A EA201590460A EA201590460A1 EA 201590460 A1 EA201590460 A1 EA 201590460A1 EA 201590460 A EA201590460 A EA 201590460A EA 201590460 A EA201590460 A EA 201590460A EA 201590460 A1 EA201590460 A1 EA 201590460A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rna
treatment
diseases caused
prevention
containing viruses
Prior art date
Application number
EA201590460A
Other languages
Russian (ru)
Other versions
EA028541B1 (en
Inventor
Владимир Евгеньевич НЕБОЛЬСИН
Сергей Владимирович БОРИСЕВИЧ
Андрей Юрьевич ЕГОРОВ
Original Assignee
Общество С Ограниченной Ответственностью "Фарминтерпрайсез"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Фарминтерпрайсез" filed Critical Общество С Ограниченной Ответственностью "Фарминтерпрайсез"
Publication of EA201590460A1 publication Critical patent/EA201590460A1/en
Publication of EA028541B1 publication Critical patent/EA028541B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к медицине и включает способ профилактики или лечения заболеваний, вызываемых (+)РНК-содержащими вирусами, предусматривающий использование эффективного количества глутарилгистамина или его фармацевтически приемлемой соли. Изобретение также относится к фармацевтической композиции для профилактики или лечения заболеваний, вызываемых (+)РНК-содержащими вирусами, содержащей эффективное количество глутарилгистамина или его фармацевтически приемлемой соли. Посредством данного изобретения решена задача предоставления нового средства, эффективного в лечении заболеваний, вызываемых (+)РНК-содержащими вирусами, которые принадлежат роду энтеровирусов или роду флавивирусов.The invention relates to medicine and includes a method for the prevention or treatment of diseases caused by (+) RNA-containing viruses, involving the use of an effective amount of glutaryl histamine or its pharmaceutically acceptable salt. The invention also relates to a pharmaceutical composition for the prevention or treatment of diseases caused by (+) RNA-containing viruses containing an effective amount of glutaryl histamine or its pharmaceutically acceptable salt. Through this invention, the task of providing a new agent effective in the treatment of diseases caused by (+) RNA-containing viruses that belong to the genus of enteroviruses or the genus of flaviviruses is solved.

EA201590460A 2012-08-30 2013-08-29 Method for the treatment and prophylaxis of diseases caused by (+)rna-containing viruses EA028541B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2012137097/15A RU2518314C2 (en) 2012-08-30 2012-08-30 Method and agent activating irf-3 for treating and preventing diseases caused by (+) rna containing viruses
PCT/RU2013/000751 WO2014035297A1 (en) 2012-08-30 2013-08-29 Method and agent for the treatment and prophylaxis of diseases caused by (+)rna-containing viruses

Publications (2)

Publication Number Publication Date
EA201590460A1 true EA201590460A1 (en) 2015-06-30
EA028541B1 EA028541B1 (en) 2017-11-30

Family

ID=50183972

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590460A EA028541B1 (en) 2012-08-30 2013-08-29 Method for the treatment and prophylaxis of diseases caused by (+)rna-containing viruses

Country Status (17)

Country Link
US (1) US9820970B2 (en)
EP (1) EP2893936B1 (en)
JP (1) JP6328638B2 (en)
CN (1) CN104684569B (en)
CA (1) CA2883908C (en)
CY (1) CY1120158T1 (en)
DK (1) DK2893936T3 (en)
EA (1) EA028541B1 (en)
ES (1) ES2667342T3 (en)
HK (1) HK1210025A1 (en)
HU (1) HUE036805T2 (en)
LT (1) LT2893936T (en)
PL (1) PL2893936T3 (en)
PT (1) PT2893936T (en)
RU (1) RU2518314C2 (en)
SI (1) SI2893936T1 (en)
WO (1) WO2014035297A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9504673B2 (en) * 2009-05-21 2016-11-29 LTD “Valenta-Intellekt” Agent for the prophylaxis and treatment of highly pathogenic infectious diseases
RU2628800C2 (en) * 2014-03-12 2017-08-22 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Amide compounds, methods for production, application as means for treatment and prevention of diseases caused by rna-containing viruses
RU2746692C1 (en) * 2020-04-14 2021-04-19 Общество С Ограниченной Ответственностью "Валента - Интеллект" Novel 2-(imidazol-4-yl)-ethanamide pentanedioic-1,5 acid compositions for treating and preventing viral diseases
RU2770518C2 (en) * 2020-02-11 2022-04-18 Общество С Ограниченной Ответственностью "Валента-Интеллект" Liquid dosage form for treatment and prevention of flu and arvi
RU2744854C1 (en) * 2020-02-11 2021-03-16 Общество С Ограниченной Ответственностью "Валента-Интеллект" Liquid dosage form for treating and preventing influenza and sars
RU2770521C2 (en) * 2020-02-11 2022-04-18 Общество С Ограниченной Ответственностью "Валента-Интеллект" Liquid dosage form for treatment and prevention of flu and arvi
CN114984030A (en) * 2022-06-23 2022-09-02 中国人民解放军海军军医大学 Application of ribavirin in preparation of tick-borne encephalitis virus resistant drugs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2141483C1 (en) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Peptide derivatives or their pharmaceutically acceptable salts, method of their synthesis, use and pharmaceutical composition
EP1023901A4 (en) * 1997-10-13 2004-10-27 Otsuka Pharma Co Ltd Ameliorant for hepatitis c remedial effect and application thereof
ATE248186T1 (en) 1998-04-30 2003-09-15 Agouron Pharma ANTIPICORNAVIRAL COMPOUNDS, THEIR PRODUCTION AND USE
RU2191594C1 (en) * 2001-04-03 2002-10-27 Григорян Седа Суреновна Method and means for stimulating resistance to infection
DE60311702T2 (en) * 2002-06-03 2007-10-31 National Health Research Institutes Treatment of flavivirus infections
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
RU2335495C2 (en) * 2005-06-15 2008-10-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" N-acyl derivatives of aminoacids, their pharmaceutically acceptable salts, pharmaceutical composition and application as hypolipidemic preparations
RU2338552C2 (en) * 2006-09-19 2008-11-20 Владимир Евгеньевич Небольсин Pharmaceutical composition for inhalation
US9504673B2 (en) * 2009-05-21 2016-11-29 LTD “Valenta-Intellekt” Agent for the prophylaxis and treatment of highly pathogenic infectious diseases
RU2496512C1 (en) * 2012-03-14 2013-10-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Method of treating viral hepatitis c

Also Published As

Publication number Publication date
SI2893936T1 (en) 2018-07-31
EP2893936A4 (en) 2016-03-16
CY1120158T1 (en) 2018-12-12
CA2883908A1 (en) 2014-03-06
US9820970B2 (en) 2017-11-21
CA2883908C (en) 2019-06-04
PT2893936T (en) 2018-05-02
RU2012137097A (en) 2014-03-10
EP2893936B1 (en) 2018-04-04
US20150209330A1 (en) 2015-07-30
EP2893936A1 (en) 2015-07-15
JP6328638B2 (en) 2018-05-23
RU2518314C2 (en) 2014-06-10
DK2893936T3 (en) 2018-05-28
EA028541B1 (en) 2017-11-30
CN104684569B (en) 2018-03-02
LT2893936T (en) 2018-06-25
HUE036805T2 (en) 2018-07-30
JP2015526513A (en) 2015-09-10
CN104684569A (en) 2015-06-03
PL2893936T3 (en) 2018-09-28
WO2014035297A1 (en) 2014-03-06
ES2667342T3 (en) 2018-05-10
HK1210025A1 (en) 2016-04-15

Similar Documents

Publication Publication Date Title
JOP20210109A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
EA201590460A1 (en) METHOD AND MEANS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY (+) RNA-CONTAINING VIRUSES
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
EA201590343A1 (en) ALKYLPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES
PH12016502355A1 (en) Pharmaceutical composition
PH12018500569A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PH12015502230A1 (en) Novel viral replication inhibitors
EA201590358A1 (en) Inhibitors of Human Immunodeficiency Virus Replication
EA201490654A1 (en) NEW INHIBITORS OF VIRAL REPLICATION
EA201590667A1 (en) ACYLAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES
PH12017501272A1 (en) Indole derivatives as dengue viral replication inhibitors
EA201790700A1 (en) MONO OR DESIGNED INDOLS AS AN INHIBITORS REPLICATION OF DENG VIRUSES
EA201690687A1 (en) REPLICATION INHIBITORS OF THE VIRUS OF IMMUNODEFICIENCY
JOP20160198B1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
EA201790576A1 (en) Spirocyclic inhibitors of katepsin C
EA201692481A1 (en) COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101
EA201690039A1 (en) RORC2 INHIBITORS AND METHODS OF THEIR APPLICATION
EA201490495A1 (en) NEW EASY DESTROYING ROCK INHIBITORS
EA201370230A1 (en) NEW ROCK INHIBITORS
MY185672A (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
EA201492161A1 (en) N-METHYL-4-BENZYLKARBAMIDOPYRIDINE CHLORIDE AND METHOD FOR ITS PREPARATION
PH12019501907A1 (en) Novel viral replication inhibitors
MY197383A (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
EA201990314A1 (en) NEW VIRAL REPLICATION INHIBITORS